{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:49:32Z","timestamp":1769734172871,"version":"3.49.0"},"reference-count":48,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T00:00:00Z","timestamp":1201737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether oral administration of rebamipide, a mucosal protective agent, is effective in the treatment of Sj\u00f6gren's syndrome (SS) in the NFS\/<jats:italic>sld<\/jats:italic> mouse model of the disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>NFS\/<jats:italic>sld<\/jats:italic> mice were given daily oral doses of rebamipide (0.3 mg\/kg of body weight or 3 mg\/kg) or vehicle alone starting from the age of 4 weeks to the age of 8 weeks. The volume of saliva and tears was monitored during and after treatment. After the final dose, histologic features of the tissues, TUNEL+ apoptotic duct cells in affected glands, T cell and cytokine function, and levels of immunoglobulin isotypes and serum autoantibodies were examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 3\u2010mg\/kg dose of rebamipide prevented the development of autoimmune lesions. The average volume of saliva in rebamipide\u2010treated mice was significantly higher than that in control mice. We found decreased TUNEL+ apoptotic duct cells in the salivary and lacrimal glands of rebamipide\u2010treated mice as compared with control mice. Rebamipide treatment suppressed the activation of CD4+ T cells and Th1 cytokines (interleukin\u20102, interferon\u2010\u03b3) associated with impaired NF\u2010\u03baB activity. Production of serum autoantibodies, IgM, and IgG1 was clearly inhibited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings demonstrate the efficacy of oral administration of rebamipide in the treatment of SS. Rebamipide represents a new therapeutic strategy for the treatment of patients with sicca symptoms caused by SS, as well as for patients with other diseases.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.23163","type":"journal-article","created":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T19:52:53Z","timestamp":1201809173000},"page":"389-400","source":"Crossref","is-referenced-by-count":36,"title":["Effective treatment with oral administration of rebamipide in a mouse model of Sj\u00f6gren's syndrome"],"prefix":"10.1002","volume":"58","author":[{"given":"Masayuki","family":"Kohashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naozumi","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Arakaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66990-5"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200009000-00007"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(95)80075-1"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.829"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141107"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00201-1"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg081"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/90935"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200108023450506"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/91070"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.2.1050"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.9.1585"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.9.5345"},{"key":"e_1_2_7_15_2","first-page":"154","article-title":"Natural autoantibodies: from \u2018horror autotoxicus\u2019 to \u2018gnothi seauton\u2019","volume":"12","author":"Avrameas S","year":"1991","journal-title":"Immunol Today"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:29:3:167"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0959-9673.2003.00358.x"},{"key":"e_1_2_7_18_2","first-page":"685","volume-title":"Fundamental immunology","author":"Ravetch JV","year":"2003"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.7.975"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005525313856"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.18.s1.13.x"},{"key":"e_1_2_7_22_2","first-page":"187","article-title":"A new mutation involving the sublingual gland in NFS\/N mice: partially arrested mucous cell differentiation","volume":"132","author":"Hayashi Y","year":"1988","journal-title":"Am J Pathol"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.6.2769"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65111-5"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.4049\/jimmunol.162.5.2488","article-title":"Fas ligand\u2010mediated exocrinopathy resembling Sj\u00f6gren's syndrome in mice transgenic for IL\u201010","volume":"162","author":"Saito I","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5312.604"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200212)32:12<3765::AID-IMMU3765>3.0.CO;2-I"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20810"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17601"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4384"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916930400022954"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000135450.78047.78"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0607-9"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115003"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(02)00397-7"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.01335.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199709000-00004"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200323120-00002"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655200750023714"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.9.5219-5224.2003"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0891-5849(94)00110-6"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90649-2"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02154.x"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1104803"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1357"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01121.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20472"},{"key":"e_1_2_7_48_2","first-page":"1551","article-title":"Use of topical cyclosporin A in a primary Sj\u00f6gren's syndrome mouse model","volume":"39","author":"Tsubota K","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0214682"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.23163","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.23163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T22:39:10Z","timestamp":1696977550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.23163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,31]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1002\/art.23163"],"URL":"https:\/\/doi.org\/10.1002\/art.23163","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,31]]}}}